This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification. This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).
Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin. Dose individually adjusted.
Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
Buenos Aires, Argentina
Capital Federal, Argentina
Corrientes, Argentina
Salta, Argentina
Zárate, Argentina